Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More

NCT01012817

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Study identifier: NCT01012817
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

Metastatic solid tumor for which curative measures do not exist (Phase I); Ovarian epithelial or primary peritoneal cancer (Phase II) refractory to platinum-based therapy or relapsed less than a year after platinum-based therapy, no more than 2 prior therapeutic regimes for ovarian or primary peritoneal cancer

Type of study:

Phase I/II study

Treatment:

28-day cycles with veliparib orally on days 1-3, 8-10, and 15-17 and topotecan hydrochloride intravenously on days 2, 9, and 16

Study sites:

Arizona
Scottsdale
Mayo Clinic in Arizona
Contact: Donald W. Northfelt 507-538-7623 Northfelt.Donald@mayo.edu

Minnesota
Rochester
Mayo Clinic
Contact: Charles Erlichman 507-538-7623 erlichman.charles@mayo.edu

Page updated 06/13/13